Tadas Trunca, MSc, MBA’s Post

🎙️ Flashback: Illuminates the Future of Biopharmaceuticals At the recent conference, our Co-founder Sarfaraz K. Niazi shared a powerful narrative that's at the heart of ABYOLO's mission – transforming biosimilars from a concept to a global healthcare solution. Highlighting the intersection of innovation and accessibility: Explored how emerging technologies like CRISPR can revolutionize biosimilar development Emphasized the critical role of bioclusters in accelerating affordable biological treatments Demonstrated how personalized medicine and biosimilars can democratize healthcare globally His insights underscore ABYOLO's core belief: innovative biosimilars are key to making advanced treatments accessible to everyone, everywhere. Our journey continues – breaking barriers, one biosimilar at a time. #Biosimilars #HealthcareInnovation #AffordableMedicine #ABYOLO #BiotechnologyBreakthrough

I am excited to be speaking at #BIOTECHX on 9/17 and 9/18. I'll be diving into "Demystifying FAIR" and exploring why "Data Governance Isn't One Size Fits All." I look forward to engaging with industry leaders on these topics! #biotechnology #datagovernance #dataanalytics #pharmaceuticals #biopharma #datascience

Dive into Australia’s biotech ecosystem at #BIOHK2024! Get ready for insights and engaging discussions with members of the Australian Biotech Mission 2024. Join us to successfully start your next clinical trial with our #australianadvantage! Taking place between September 11-14, this year's event will feature discussions on cutting-edge biotech developments, raise awareness of innovative research and products, and inspire interaction and engagement to foster new collaborations. For 360biolabs, this event provides us with another valuable opportunity to promote the advantages of the Australian life sciences ecosystem, with our partners in our mission Acclime, Adjutor Healthcare Group, Alithia Life Sciences, Nucleus Network, SYNthesis BioVentures and TrialKey, sponsored by APAC Financial Services. You can find us at Booth # A1-2, E1-2, located at Hall 3DE within the Convention Centre. If you’re attending BIOHK2024 and want to discover how we can support your biopharmaceutical goals, let’s meet!  Connect with Angela Luttick, Sharon S., and Han Li, reach out to us at bd@360biolabs.com, message us on the partnering platform, or here on LinkedIn to schedule a one-on-one meeting.    Looking forward to engaging with you and exploring new opportunities together!    #360biolabs #bioanalyticallab #theaustralianadvantage #BIOHK #AustralianDelegation #BioTechOpportunities #biotechnology #lifesciences

We are glad to introduce our upcoming Global Bioprocessing & Bio Technology Summit taking place on the 22nd – 23rd of May 2025 in Berlin, Germany. In a world where every cell holds a secret and is a realm for discovery, the Bioprocessing Summit returns as the catalyst for unraveling the complexities of advanced therapeutic interventions. Join the global biotech conference with experts as they share insights and deliberate on pertinent and trending issues in the industry. Bio Tec Summit is a premier investor conference committed to creating a platform for biotechnology companies, offering them a unique opportunity to showcase their innovations and engage one-to-one with investors and biopharmaceutical executives. While spreading enlightenment on these burning topics, there will be discussions on the application of environmentally conscious and socially responsible practices in the field of Bioprocessing. By examining case studies and drawing insights from lessons learned, the summit aids in shaping the very future we have dared to imagine. International Bioprocessing Summit: Uniting Innovators in Bio-Tech Conference Enjoy uniting Biotech Innovators, where each discovery propels us deeper into the realms of limitless potential. Embark on a journey of discovery at our Global Bioprocessing Summits and Biotech Conferences, where biotech industry leaders converge to explore cutting-edge advancements and foster collaboration. Kindly visit our website for more information about the event: https://lnkd.in/e2jPzdep #Bioprocessing #Biotechnology #pharmaceutical #CW

"(...) Medicine Development and commercialization will be dominated by Data companies with Biotech and Pharma companies playing the role of a substrate supplier to algorithms" (Dr. Michael Zaiac) The writing is on the wall. If this happens, it will be a seismic shift affecting all aspects of healthcare. For many established players, this will pose a major threat to their business model. But within this threat, there is also opportunity. For patients, for Data companies - and for a few Pharma companies who get it right. Thanks Michael Zaiac for spelling it out and Bora Erdemli for posting! #futureofhealthcare #datadrivenmedicine #genAI

Andy Allen and Tifelle Reisinger joined the 2024 Innovate2Translate symposium today. BioCurate Pty Ltd thanks the Melbourne Therapeutics Organising Committee for an excellent symposium! BioCurate Pty Ltd sponsored the Funders panel session facilitated by Chris Porter (Monash Institute of Pharmaceutical Sciences ), with our own Andy Allen, as well as Michael Bettess (Brandon Capital), Siro Perez (IP Group plc), Michelle H. (Tin Alley Ventures) and Joey Man (Tenmile). The session sparked engaging and insightful conversations with great advice from the panel. Few takeaways on what these funders are looking for and some tips. - Differentiation: what makes your product special and have IP to protect it. - Sound path to market with clinical input and regulatory strategy - Biotech is a team sport. Build a collaborative team with drug development experience, and leverage the expertise and network of your investors - Building a company is a long but rewarding game. Incentivise founders to have skin in the game and keep them involved as entrepreneurs or scientific advisors - Investors talk to each other regularly about de-risking projects together to significantly move the needle towards the next inflection point - Value in single asset versus platform - Invest in first-in-class versus best-in-class molecules with transformational improvement for patients #I2T2024 #BioCurate #Innovation #drugtranslation #MedicalResearch

https://lnkd.in/emGAa7S3 Denmark is increasingly becoming a central player in the pharmaceutical world, with innovation, talent, and investments propelling the industry forward. The country is home to some of the biggest pharma companies globally, supported by cutting-edge research institutions, and a collaborative ecosystem that connects private companies, public sector entities, and academia. The Danish pharma industry is growing at an impressive pace, driven by robust support for research and development, a highly skilled workforce, and a strong focus on sustainability and life sciences innovation. The country's infrastructure and regulatory frameworks are well-suited for rapid growth and pioneering advancements, making it an ideal location for both established pharma giants and emerging biotech startups. With the global demand for new treatments, vaccines, and healthcare solutions on the rise, Denmark is poised to play a significant role in meeting these challenges. From developing innovative therapies to setting new standards in sustainable healthcare practices, Denmark is the place to be for anyone in the pharma sector. And this is just the beginning – the future of pharma in Denmark looks incredibly promising! 💼🌍💊 #Pharma #Biotech #Innovation #Healthcare #Denmark #Engineering

📣 Nordic Biotechs Beyond Borders: Public-Stage Nordic Biotech’s in Today's Markets Join our panel of #BiotechLeaders as they discuss: ·  The current state of the public markets ·  Effective strategies for Nordic biotechs to enter and establish a foothold in new international markets, including considerations for regulatory compliance and cultural nuances ·  The importance of building robust global networks and partnerships, exploring how collaborations with international stakeholders contribute to market access, distribution, and product adoption. ·  How public stage Nordic biotechs can navigate the complexities of sustaining growth, maintaining innovation momentum, and meeting the expectations of shareholders and the broader market post-IPO ·  How strategic partnerships and collaborations contribute to market presence, product development, and overall competitiveness 🎙 Hear from: · Don deBethizy, Member Board of Directors, argenx · Renee Aguiar-Lucander, CEO, Calliditas Therapeutics · Jens Lindberg, CEO, Medivir AB · Per Andersson, CEO, XSPRAY PHARMA AB (PUBL) · Søren Bregenholt, CEO, Alligator Bioscience AB · Göran Forsberg, CEO, Cantargia AB Find out more: https://lnkd.in/ew-Xj7d8 #LSXNordic #Biotech

Last week, our CEO Luigi Aurisicchio attended the 4th Consortium Meeting of the MIRIA EU Project in Prague, hosted by Charles University. Takis, alongside valuable partners from across Europe, holds a central role in this initiative. The MIRIA project aims to develop wide-range antimicrobial nanocoatings for surfaces used in environments such as hospitals, where cross-contamination and contagion risks are significant. At Takis, we are responsible for assessing the antiviral properties of these nanocoatings by evaluating viral infectivity on mammalian cells after prolonged exposure to coated or uncoated materials. Our work aims to determine the nanocoatings' ability to neutralize the virus in laboratory settings, with the goal of selecting the best candidates for pilot-scale production and potential market entry within three years. This meeting provided the opportunity to engage with our European partners and discuss the project developments and milestones achieved so far. Being part of such a diverse and talented consortium is truly enriching, offering us valuable opportunities for learning and growth! #pharma #pharmaceutical #biotech #biotechnology #research #networking #teamwork

Recently, the leadership teams of US Pharmacopeia and Biotechnology Industry Research Assistance Council (BIRAC) came together to further our shared vision for advancing India's biomanufacturing sector. This pivotal meeting included Ronald Piervincenzi, CEO, USP, Jaap V. , CSO, USP along with Dr. Jitender Kumar, MD, BIRAC, and Dr. Sonia Gandhi, Deputy General Manager & Head, Regulatory Affairs & Policy Advocacy, BIRAC. USP and BIRAC officially completed the signing of the Letter of Intent, a significant milestone first announced at Global Bio India 2024. This collaboration underscores a shared vision to build capabilities in biomanufacturing, enhancing the quality of biopharmaceuticals and drive innovation in India's biomanufacturing ecosystem. We are excited to continue this partnership and work together to create impactful solutions that foster sustainable growth in the biopharmaceutical landscape.